Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point (Q44579172)
Jump to navigation
Jump to search
scientific article published on 3 November 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point |
scientific article published on 3 November 2012 |
Statements
1 reference
Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point (English)
1 reference
David M Brown
1 reference
Eric Chen
1 reference
Angeline Mariani
1 reference
James C Major
1 reference
SAVE Study Group
1 reference
3 November 2012
1 reference
1 reference
120
1 reference
2
1 reference
349-354
1 reference
Identifiers
1 reference
1 reference